Cargando…
Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects
AIMS: To demonstrate the bioequivalence of macitentan/tadalafil fixed‐dose combination (FDC) tablets with single‐component tablets of macitentan and tadalafil in healthy subjects. METHODS: Studies AC‐077‐101 and AC‐077‐103 were single‐centre, open‐label, single‐dose, 2‐period, randomized, crossover...
Autores principales: | Grill, Simon, Bruderer, Shirin, Sidharta, Patricia N., Antonova, Mariya, Globig, Susanne, Carlson, James, Schultz, Armin, Csonka, Dénes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688529/ https://www.ncbi.nlm.nih.gov/pubmed/32374030 http://dx.doi.org/10.1111/bcp.14347 |
Ejemplares similares
-
Relative bioavailability of a pediatric dispersible tablet and adult film‐coated tablet of macitentan in healthy volunteers
por: Sidharta, Patricia N., et al.
Publicado: (2020) -
Bioequivalence and food effect of a fixed‐dose combination of macitentan and tadalafil: Adaptive design in the COVID‐19 pandemic
por: Csonka, Dénes, et al.
Publicado: (2021) -
Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects
por: Csonka, Dénes, et al.
Publicado: (2019) -
Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
por: Bruderer, Shirin, et al.
Publicado: (2011) -
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)